STAT

MARCH 1, 2024

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program. Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments.

Drug Pricing 292

Drug Pricing 292

STAT

FEBRUARY 1, 2024

WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

Drug Pricing 318

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 318

STAT

MAY 6, 2024

The changing landscape of drug pricing policy in the U.S. Drug policy changes are being influenced by perceptions of the value of novel medicines relative to their budgetary impacts, with some believing that many medicines may not be worth their cost, creating an important role for health technology assessments (HTA).

Drug Pricing 349

Drug Pricing 349

STAT

FEBRUARY 1, 2024

So my enterprising colleague John Wilkerson trekked up to Wilmington to give you an inside view on how a key judge viewed arguments in the first court test of the new Medicare drug price negotiation program. Read the rest…

Drug Pricing 203

Drug Pricing 203

STAT

FEBRUARY 8, 2024

Bernie Sanders’ prescription drug pricing theater. WASHINGTON — Call it Sen. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked.

Drug Pricing 267

Drug Pricing 267

STAT

MAY 8, 2023

EQRx, a company that aimed to lower drug prices by introducing inexpensive me-too medicines, said Tuesday that it has abandoned that plan and is laying off nearly 60% of its workforce. Continue to STAT+ to read the full story…

Drug Pricing 319

Drug Pricing Hospitals 319

STAT

FEBRUARY 8, 2024

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Drug Pricing 285

Drug Pricing Diabetes 285

STAT

AUGUST 24, 2023

At the start and halfway points of each year, many pharmaceutical companies raise drug prices to bolster revenue and reportedly fund new research. “It’s not just all selling new drugs,” said Juliette Cubanski, deputy director of the Program on Medicare Policy at Kaiser Family Foundation.

Drug Pricing 228

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 228

STAT

SEPTEMBER 8, 2022

The passage of the Inflation Reduction Act brings a new era to drug pricing in the United States. After decades of being an outlier, it now joins every other developed nation in having the federal government engaged in negotiating drug pricing.

Drug Pricing 245

Drug Pricing 245

STAT

DECEMBER 6, 2023

judge ruled that Minnesota must temporarily halt a controversial law that is designed to provide transparency into prescription drug pricing over concerns that it is unconstitutional. In a victory for the pharmaceutical industry, a U.S.

Drug Pricing 293

Drug Pricing Pharmaceutical Manufacturing 293

STAT

MARCH 9, 2023

WASHINGTON — President Biden made lowering drug prices a key part of his budget with proposals to expand Medicare drug price negotiation, squeeze more rebates out of drug companies, and lower the cost of insulin for everyone with insurance. The request made Thursday also details a $7.2

Drug Pricing 243

Drug Pricing 243

PharmaVoice

AUGUST 18, 2022

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

Drug Pricing 262

Drug Pricing 262

STAT

MAY 11, 2023

is pursuing the drug pricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), The markup came just a day after the same panel held a major hearing on PBM and drugmakers’ role in high insulin prices. Chairman Bernie Sanders (I-Vt.)

Drug Pricing 275

Drug Pricing Packaging 275

STAT

AUGUST 15, 2023

As STAT reported recently, the Senate Committee on Health, Education, Labor, and Pensions (HELP) has indicated that it will not consider the nomination of Monica Bertagnolli as director of the National Institutes of Health unless she pledges to take specific steps to reduce drug prices. Read the rest…

Drug Pricing 238

Drug Pricing 238

STAT

OCTOBER 2, 2023

… A federal court judge allowed the new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional , STAT reports. Meanwhile, Novo Nordisk became the latest pharmaceutical company to file a lawsuit against the Medicare drug price negotiation program , Bloomberg Law tells us. The

Drug Pricing 254

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 254

STAT

MAY 24, 2023

The goal is to give states more leverage in price negotiations by forcing drugmakers to share and publish details about their pricing data. The government would collect specific drug pricing information from makers of up to 10 particularly high-cost drugs.

Drug Pricing 238

Drug Pricing 238

STAT

JANUARY 23, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at some polarizing cancer data, a strange CEO transition, and the importance of New Year cheer. Read the rest…

Drug Pricing 179

Drug Pricing Drug Development 179

STAT

MARCH 8, 2023

WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive program will start to negotiate drug prices — let alone the substantive ones, Medicare chief Meena Seshamani said at a STAT event Tuesday.

Drug Pricing 208

Drug Pricing 208

STAT

JULY 26, 2023

They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.

Drug Pricing 228

Drug Pricing Packaging Pharmaceutical Companies Pharmaceutical Companies 228

PharmaVoice

AUGUST 31, 2023

Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.

Drug Pricing 147

Drug Pricing 147

STAT

DECEMBER 1, 2022

At a time when many Americans are clamoring for more transparency into prescription drug pricing, one key provider of that data is making it harder to access the information.

Drug Pricing 239

Drug Pricing Packaging 239

STAT

JULY 22, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin.

Drug Pricing 286

Drug Pricing 286

STAT

NOVEMBER 2, 2023

WASHINGTON — A key Senate panel announced it will consider more policies to regulate pharmacy middlemen and ensure patients aren’t paying more than insurers do for medications. The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) and Mike Crapo (R-Idaho) is slated to be marked up on Nov.

Packaging 347

Packaging Drug Pricing 347

Drug Patent Watch

JANUARY 9, 2024

A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in… The post NPR on how low Drug Prices can Shortages appeared first on DrugPatentWatch - Make Better Decisions.

Drug Pricing 110

Drug Pricing 110

STAT

JULY 5, 2024

WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry its latest in a string of legal losses. The company had argued before the U.S.

Drug Pricing 324

Drug Pricing Diabetes 324

Pharmaceutical Commerce

APRIL 8, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features.

Drug Pricing 105

Drug Pricing 105

STAT

MARCH 10, 2023

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products.

Drug Pricing 241

Drug Pricing 241

STAT

JULY 6, 2023

The trade group for generic drug companies has filed a lawsuit alleging a Minnesota law that is designed to provide transparency into prescription drug pricing is unconstitutional, the latest effort to push back against states attempting to lower the cost of medicines.

Drug Pricing 221

Drug Pricing 221

STAT

MARCH 20, 2024

WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis from nonpartisan congressional budget experts.

Drug Pricing 330

Drug Pricing Diabetes 330

Drug Channels

MARCH 6, 2023

Experts from across the industry will discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*

Drug Pricing 98

Drug Pricing 98

STAT

DECEMBER 7, 2023

The framework will detail when the agency might assert this authority, and endorse using drug prices when deciding. National Institutes of Health to more broadly use march-in rights, a policy that allows it to seize patents from drugmakers whose products rely on federally funded research. billion , STAT writes.

Drug Pricing 235

Drug Pricing 235

STAT

SEPTEMBER 20, 2023

T wo months ago, Sen. Bernie Sanders (I-Vt.) moved a step closer to an idea he has championed for some time — awarding prizes, instead of patents, for inventing medicines.

Drug Pricing 344

Drug Pricing 344

STAT

MARCH 27, 2023

When Moderna CEO Stéphane Bancel was called before a Senate committee last week to defend his company’s decision to raise the price of its Covid vaccine, things went largely as one would expect. Progressives tried to pin the Moderna billionaire down as a symbol of corporate greed. Mitt Romney delivered a paean to the free market.

Drug Pricing 246

Drug Pricing Vaccines 246

STAT

JULY 24, 2023

You don’t have to be an economist to understand the law of demand: The higher the price, the less likely a customer is to buy a product. It’s not always the customer who decides that the price is too high. This, of course, limits how much companies can charge. Often, it’s the insurer.

Drug Pricing 246

Drug Pricing 246

STAT

JUNE 7, 2023

BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing.

Drug Pricing 360

Drug Pricing Drug Development 360

STAT

SEPTEMBER 8, 2023

After the recent announcement of the first 10 drugs selected for Medicare price negotiation, much has been discussed about the drugs that were selected and the magnitude of price decreases that can be achieved. Less attention has been given to what this all means for Medicare beneficiaries. 1, 2026.

Drug Pricing 315

Drug Pricing 315

BioPharma Dive

AUGUST 22, 2023

The pharma’s suit, which claims Medicare’s new power to negotiate certain drug prices is unconstitutional, comes days before the agency will reveal the first 10 medicines to be included under the plan.

Drug Pricing 97

Drug Pricing 97